Procter & Gamble Health Limited has informed the Exchange regarding Board meeting held on August 01, 2025.
PGHL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.6 pts more than Nifty Microcap 250 and 7.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Procter & Gamble Health reported strong Q1 FY26 results with revenue from operations of ₹33,874 lakhs, up about 19.3% from ₹28,388 lakhs in the same quarter last year. Total income rose to ₹34,277 lakhs from ₹28,601 lakhs. Net profit surged to ₹6,618 lakhs from ₹1,678 lakhs, with basic and diluted EPS at ₹39.87 versus ₹22.27 (before exceptional items). The profit jump is partly inflated because the year-ago quarter had a ₹2,019 lakh one-time charge related to the closure and sale of its Goa injection plant. Costs as a share of revenue fell meaningfully, lifting operating margins significantly year-on-year. Statutory auditor Haribhakti & Co. LLP issued an unmodified limited review report.
Strong quarter for shareholders — revenue growth in the high teens and a sharp jump in profits signal healthy demand and improved cost efficiency. Investors should note last year's base was depressed by a one-off plant-closure charge, so the headline PAT growth overstates underlying improvement, though the underlying business momentum remains clearly positive.